Quotient Limited (QTNT) EPS Estimated At $-0.36

October 2, 2018 - By Ellis Scott

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 1.09 in 2018 Q2. Its up 0.04, from 1.05 in 2018Q1. It increased, as 22 investors sold Quotient Limited shares while 11 reduced holdings. 27 funds opened positions while 9 raised stakes. 26.05 million shares or 3.83% less from 27.08 million shares in 2018Q1 were reported.
Hudson Bay Capital Mgmt Ltd Partnership owns 800,000 shares for 0.09% of their portfolio. Park West Asset Mgmt Lc holds 0.09% or 300,087 shares in its portfolio. Highbridge Mgmt, New York-based fund reported 76,591 shares. Deutsche Bank Ag holds 10,518 shares. S Squared Limited Company has 1.9% invested in Quotient Limited (NASDAQ:QTNT). Panagora Asset Inc accumulated 0.01% or 161,938 shares. Royal Comml Bank Of Canada invested in 2,000 shares. Goldman Sachs reported 235,728 shares stake. Jefferies Grp Inc Limited, New York-based fund reported 66,156 shares. Bnp Paribas Arbitrage Sa reported 0% in Quotient Limited (NASDAQ:QTNT). Moreover, Balyasny Asset Limited Liability Corp has 0% invested in Quotient Limited (NASDAQ:QTNT) for 49,046 shares. Point72 Asset Management L P reported 395,900 shares or 0.01% of all its holdings. State Street has 0% invested in Quotient Limited (NASDAQ:QTNT) for 10,100 shares. Moreover, Knott David M has 0.5% invested in Quotient Limited (NASDAQ:QTNT). One Trading Lp accumulated 6,142 shares or 0% of the stock.

Since May 22, 2018, it had 1 buying transaction, and 0 selling transactions for $2.90 million activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.36 EPS on October, 29.They anticipate $0.22 EPS change or 37.93 % from last quarter’s $-0.58 EPS. After having $-0.55 EPS previously, Quotient Limited’s analysts see -34.55 % EPS growth. The stock decreased 4.37% or $0.33 during the last trading session, reaching $7.22. About 202,032 shares traded. Quotient Limited (NASDAQ:QTNT) has risen 46.64% since October 2, 2017 and is uptrending. It has outperformed by 31.02% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $391.63 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

More recent Quotient Limited (NASDAQ:QTNT) news were published by: Benzinga.com which released: “41 Stocks Moving In Tuesday’s Mid-Day Session” on September 25, 2018. Also Nasdaq.com published the news titled: “Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key …” on September 25, 2018. Nasdaq.com‘s news article titled: “Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference” with publication date: September 26, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.